金吾财讯 | 礼来公司(LLY)周四宣布，其新获批的减肥药Foundayo(奥福格列隆)即日起正式登陆美国零售药店，进一步扩大供应范围，与诺和诺德(NVO)展开正面竞争。
本月初，FDA批准该药物用于肥胖或超重成年人的每日一次治疗，礼来随即通过自有网站接受处方，后拓展至远程医疗提供商，如今完成零售药店布局。其最低剂量月用量对现金支付顾客定价为每月149美元。
作为全球第二款获批的口服GLP-1减肥药，Foundayo的上市将加剧礼来与诺和诺德的市场争夺。诺和诺德今年1月推出口服Wegovy后，已推出多月订阅计划，为自费患者提供折扣，巩固市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.